News & Insights
All the latest News and Insights from OHE, plus an archive of our monthly email bulletin.
Latest Insights
Seven reflections on the UK EQ-5D-5L value set – and what comes next
The long-awaited UK EQ-5D-5L value set has been published, marking a key moment for health technology assessment. Its adoption by NICE is set to shape how health-related quality of life is valued, raising important questions for future HTA decisions.
Europe’s pharmaceutical policy choices – And what the United States stands to learn
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw from Europe’s experience with pharmaceutical pricing and innovation. As a participant, my key takeaways focused on understanding the trade-offs underpinning EU and UK drug pricing policy and the broader impact on innovation for both sides of the Atlantic.
Around The World in HTAs: France – Three Core HTA Values
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
Why do we expect obesity medicines to work differently?
Weight regain after stopping GLP-1 medicines isn’t a treatment failure — it shows that obesity is a chronic, relapsing condition. Like other long-term therapies, benefits last only while treatment continues. Reframing obesity this way can improve outcomes and reduce stigma.
Latest News
OHE responds to the 2025 UK Budget
Commenting on the newly announced 2025 UK Budget, Professor Graham Cookson, Chief Executive of the Office of Health Economics, said: “The NHS’ long-term sustainability will only come…
New research reveals, in carers’ own words, the multidimensional burden of caring for leukemia patients
Today, the Acute Leukemia Advocates Network (ALAN) and the Office of Health Economics (OHE published a first-of-its-kind qualitative study of informal carers across 6 countries.
New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy
A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
A newly released report commissioned by Moderna modelled a one-year scenario without annual COVID-19 autumn vaccinations.
OHE responds to the NHS Ten Year Plan
Professor Graham Cookson responds to the Ten Year Health Plan for England.
OHE statement on 2025 Spending Review
Professor Graham Cookson responds to Chancellor’s Spending Review announcement boosting NHS spend by 3%.
